Skin permeation enhancer compositions using acyl lactylates

• US 5,882,676 A
• Filed: 05/26/1995
• Issued: 03/16/1999
• Est. Priority Date: 05/26/1995
• Status: Expired due to Term

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Lee, Eun Soo, Yum, Su Il
• Primary Examiner(s): Webman, Edward J.
• Application Number:
  US08/452,468
• Time in Patent Office: 1,390 Days
• Field of Search: 424/449, 424/448, 514/946, 514/947, 604/304, 604/307
• US Class Current: 424/449
• CPC Class Codes: A61K 47/14 Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/7084 Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Abstract

The present invention is directed to the transdermal administration of a drug together with a suitable amount of an acyl lactylate permeation enhancer. The invention includes a transdermal drug delivery device comprising a matrix adapted to be placed in drug- and- permeation enhancer-transmitting relation with a skin site. The matrix contains sufficient amounts of an acyl lactylate permeation enhancer and drug, in combination, to continuously administer drug to the systemic circulation of a patient at a therapeutically effective rate. The invention is also directed to compositions and methods for transdermal administration of a drug together with an acyl lactylate permeation enhancer, alone or in combination with other enhancers.

Claims

1. A method for enhancing the transdermal flux during transdermal administration of at least one drug to the systemic circulation of a patient, at a therapeutically effective rate, by permeation through a body surface or membrane, comprising:

(a) simultaneously administering, to the body surface or membrane, at least one drug; and

(b) a permeation-enhancing amount of an acyl lactylate permeation enhancer represented by the general structure R--CO--(OCHCH₃ CO)_n --OH where R is a straight or branched alkyl or aryl group consisting of 3 to 20 carbons and n=1 to 10;

sufficient to substantially increase the permeability of the body surface or membrane to the drug in order to systemically deliver said drug to a patient at a therapeutically effect rate.

2. A method according to claim 1 further comprising simultaneously coadministering a permeation-enhancing amount of one or more of the permeation enhancers selected from the group consisting of monoglycerides or mixtures of monoglycerides of fatty acids, lauramide diethanolamine, esters of fatty acids having from about 10 to 20 carbon atoms, and lower C_1-4 alcohols.

3. A method according to claim 1 wherein the acyl lactylate is lauroyl lactylic acid.

4. A method according to claim 1 wherein the acyl lactylate is caproyl lactylic acid.

5. A method according to claim 1 wherein the drug is testosterone.

6. A method according to claim 1 wherein the drug is progesterone.

7. A method according to claim 1 wherein the drug is administered to the systemic circulation of said patient at a therapeutically effective rate throughout a substantial portion of an administration period of at least about 10 hours.

8. A method for enhancing the flux of a drug administered from a transdermal drug delivery device through a body surface or membrane, said device of the type comprising a backing layer, a drug reservoir layer on the skin proximal side of the backing layer and a means for maintaining the device in drug transmitting relationship with said body surface or membrane throughout an administration period, said method comprising:

providing said transdermal drug delivery device with an acyl lactylate permeation enhancer in an amount sufficient to substantially increase the permeability of the body surface or membrane to the drug in order to systemically deliver said drug to a patient at a therapeutically effective rate, said acyl lactylate being represented by the general structure R--CO--(OCHCH₃ CO)_n --OH where R is a straight or branched alkyl or aryl group consisting of 3 to 20 carbon atoms and n=1 to 10.

9. The method according to claim 8 wherein the acyl lactylate is selected from lauroyl lactylic acid and caproyl lactylic acid.

10. The method according to claim 8 wherein the drug is selected from testosterone and progesterone.

11. The method according to claim 8 wherein the acyl lactylate is dispersed within the drug reservoir.

12. The method of claim 11 wherein the means for maintaining the device in drug transmitting relationship comprises a separate adhesive layer.

13. The method according to claim 8 wherein the means for maintaining the device in drug transmitting relationship comprises a pressure sensitive adhesive which also functions as the drug reservoir.

14. A device for the trandermal administration of at least one drug to the systemic circulation of a patient at a therapeutically effective rate, by permeation through a body surface or membrane, comprising:

(a) a first reservoir comprising at least one drug and a permeation enhancing-amount of an acyl lactylate permeation enhancer represented by the general structure R--CO--(OCHCH₃ CO)_n --OH where R is a straight or branched alkyl or aryl group consisting of 3 to 20 carbons and n=1 to 10;

(b) a second reservoir comprising an additional amount of said permeation enhancer and substantially free of said drug;

(c) a rate controlling membrane between the first reservoir and the second reservoir, said first reservoir positioned on the skin facing side of said rate controlling membrane and said second reservoir positioned on the skin-distal side of said rate controlling membrane;

(d) means for maintaining said first and second reservoirs in drug- and permeation enhancer- transmitting relation with the body surface or membrane, wherein the drug is delivered to the systemic circulation of a patient at a therapeutically effective rate.

15. A device according to claim 14 wherein the acyl lactylate is caproyl lactylic acid.

16. A device according to claim 14 wherein the acyl lactylate is lauroyl lactylic acid.

17. A device according to claim 14 wherein the drug is testosterone.

18. A device according to claim 14 wherein the drug is progesterone.

19. A device according to claim 14 wherein the acyl lactylate permeation enhancer is combined with a permeation-enhancing amount of one or more of the permeation enhancers selected from the group consisting of monoglycerides or mixtures of monoglycerides of fatty acids, lauramide diethanolamine, esters of fatty acids having from about 10 to 20 carbon atoms, and lower C_1-4 alcohols.